vs
Side-by-side financial comparison of CLARIVATE PLC (CLVT) and Bio-Techne (TECH). Click either name above to swap in a different company.
CLARIVATE PLC is the larger business by last-quarter revenue ($585.5M vs $295.9M, roughly 2.0× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -6.9%, a 19.7% gap on every dollar of revenue. On growth, CLARIVATE PLC posted the faster year-over-year revenue change (-1.4% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -5.1%).
Clarivate Plc is a British-American publicly traded analytics company that operates a collection of subscription-based services, in the areas of bibliometrics and scientometrics; business and market intelligence, and competitive profiling for pharmacy and biotech, patents, and regulatory compliance; trademark protection, and domain and brand protection. Clarivate calculates the impact factor of scientific journals, using data from its Web of Science product family, that also includes services...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CLVT vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $585.5M | $295.9M |
| Net Profit | $-40.2M | $38.0M |
| Gross Margin | 67.2% | 64.6% |
| Operating Margin | 5.2% | 18.4% |
| Net Margin | -6.9% | 12.8% |
| Revenue YoY | -1.4% | -6.4% |
| Net Profit YoY | 61.3% | 68.3% |
| EPS (diluted) | $-0.06 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $295.9M | ||
| Q3 25 | $623.1M | — | ||
| Q2 25 | $621.4M | $317.0M | ||
| Q1 25 | $593.7M | $316.2M | ||
| Q4 24 | $663.0M | $297.0M | ||
| Q3 24 | $622.2M | $289.5M | ||
| Q2 24 | $650.3M | $306.1M |
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $38.0M | ||
| Q3 25 | $-28.3M | — | ||
| Q2 25 | $-72.0M | $-17.7M | ||
| Q1 25 | $-103.9M | $22.6M | ||
| Q4 24 | $-191.8M | $34.9M | ||
| Q3 24 | $-65.6M | $33.6M | ||
| Q2 24 | $-304.3M | $40.6M |
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | 64.6% | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 67.2% | 62.7% | ||
| Q1 25 | 65.1% | 67.9% | ||
| Q4 24 | 65.7% | 65.3% | ||
| Q3 24 | 66.2% | 63.2% | ||
| Q2 24 | 67.2% | 66.4% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | 18.4% | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 1.1% | -7.5% | ||
| Q1 25 | -3.5% | 12.2% | ||
| Q4 24 | -9.4% | 16.0% | ||
| Q3 24 | 3.5% | 13.8% | ||
| Q2 24 | -36.9% | 15.0% |
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | 12.8% | ||
| Q3 25 | -4.5% | — | ||
| Q2 25 | -11.6% | -5.6% | ||
| Q1 25 | -17.5% | 7.1% | ||
| Q4 24 | -28.9% | 11.7% | ||
| Q3 24 | -10.5% | 11.6% | ||
| Q2 24 | -46.8% | 13.3% |
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $0.24 | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.11 | $-0.11 | ||
| Q1 25 | $-0.15 | $0.14 | ||
| Q4 24 | $-0.27 | $0.22 | ||
| Q3 24 | $-0.09 | $0.21 | ||
| Q2 24 | $-0.46 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $4.3B | $260.0M |
| Stockholders' EquityBook value | $4.8B | $2.0B |
| Total Assets | $10.9B | $2.5B |
| Debt / EquityLower = less leverage | 0.89× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $172.9M | ||
| Q3 25 | $318.7M | — | ||
| Q2 25 | $362.6M | $162.2M | ||
| Q1 25 | $354.0M | $140.7M | ||
| Q4 24 | $295.2M | $177.5M | ||
| Q3 24 | $388.5M | $187.5M | ||
| Q2 24 | $376.4M | $152.9M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $260.0M | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | $346.0M | ||
| Q1 25 | $4.5B | $330.0M | ||
| Q4 24 | $4.5B | $300.0M | ||
| Q3 24 | $4.6B | $300.0M | ||
| Q2 24 | $4.6B | $319.0M |
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $2.0B | ||
| Q3 25 | $4.9B | — | ||
| Q2 25 | $5.0B | $1.9B | ||
| Q1 25 | $5.0B | $2.0B | ||
| Q4 24 | $5.1B | $2.1B | ||
| Q3 24 | $5.5B | $2.1B | ||
| Q2 24 | $5.6B | $2.1B |
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $2.5B | ||
| Q3 25 | $11.2B | — | ||
| Q2 25 | $11.4B | $2.6B | ||
| Q1 25 | $11.5B | $2.6B | ||
| Q4 24 | $11.5B | $2.7B | ||
| Q3 24 | $12.0B | $2.7B | ||
| Q2 24 | $12.1B | $2.7B |
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | 0.13× | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | 0.18× | ||
| Q1 25 | 0.90× | 0.16× | ||
| Q4 24 | 0.88× | 0.14× | ||
| Q3 24 | 0.84× | 0.14× | ||
| Q2 24 | 0.83× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $134.7M | — |
| Free Cash FlowOCF − Capex | $78.9M | — |
| FCF MarginFCF / Revenue | 13.5% | — |
| Capex IntensityCapex / Revenue | 9.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $333.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | — | ||
| Q3 25 | $181.1M | — | ||
| Q2 25 | $116.3M | $98.2M | ||
| Q1 25 | $171.2M | $41.1M | ||
| Q4 24 | $141.3M | $84.3M | ||
| Q3 24 | $202.9M | $63.9M | ||
| Q2 24 | $126.2M | $75.5M |
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | — | ||
| Q3 25 | $115.5M | — | ||
| Q2 25 | $50.3M | $93.3M | ||
| Q1 25 | $110.3M | $31.0M | ||
| Q4 24 | $59.1M | $77.5M | ||
| Q3 24 | $126.3M | $54.7M | ||
| Q2 24 | $60.3M | $57.5M |
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 18.5% | — | ||
| Q2 25 | 8.1% | 29.4% | ||
| Q1 25 | 18.6% | 9.8% | ||
| Q4 24 | 8.9% | 26.1% | ||
| Q3 24 | 20.3% | 18.9% | ||
| Q2 24 | 9.3% | 18.8% |
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | — | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 10.6% | 1.5% | ||
| Q1 25 | 10.3% | 3.2% | ||
| Q4 24 | 12.4% | 2.3% | ||
| Q3 24 | 12.3% | 3.2% | ||
| Q2 24 | 10.1% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
